{"id":484661,"date":"2010-03-25T10:14:52","date_gmt":"2010-03-25T14:14:52","guid":{"rendered":"tag:www.hepatitis-central.com,2010:\/mt\/\/1.793"},"modified":"2010-03-29T10:18:03","modified_gmt":"2010-03-29T14:18:03","slug":"preferred-dosing-schedule-pledged-by-hcv-drug-candidate","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/484661","title":{"rendered":"Preferred Dosing Schedule Pledged by HCV Drug Candidate"},"content":{"rendered":"<p>Zalbin is a Hepatitis C drug in development that could lead to the highly desired monthly or bi-monthly dosing.<\/p>\n<p>Human Genome Sciences reports hepatitis drug study<\/p>\n<p>The Associated Press  March 24, 2010<\/p>\n<p>ROCKVILLE, Md.<\/p>\n<p>Human Genome Sciences Inc. said Wednesday a midstage study of the potential hepatitis C treatment Zalbin showed a monthly dose of the drug candidate could be as effective as a weekly dose of the standard treatment.<\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/www.businessweek.com\/ap\/financialnews\/D9EL00D82.htm\">http:\/\/www.businessweek.com\/ap\/financialnews\/D9EL00D82.htm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zalbin is a Hepatitis C drug in development that could lead to the highly desired monthly or bi-monthly dosing. Human Genome Sciences reports hepatitis drug study The Associated Press March 24, 2010 ROCKVILLE, Md. Human Genome Sciences Inc. said Wednesday a midstage study of the potential hepatitis C treatment Zalbin showed a monthly dose of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-484661","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/484661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=484661"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/484661\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=484661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=484661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=484661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}